ClinicalTrials.gg
CompletedNCT03508011Updated Mar 30, 2021

A Study of IMP4297 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of IMP4297 in Advanced Solid Tumours, Breast Cancer and Ovarian Cancer, sponsored by Impact Therapeutics, Inc.. Completed at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-03-30.

Sponsored by Impact Therapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Aug 2017, registered Jan 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
57
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,928 studies in Breast Neoplasms with a site in China — 866 open to participants now, 1,064 under way, 210 of them phase 3. Breast Neoplasms · China.

Enrollment
1,113th of 1,519
57 · median 120
Started
2017
with 66 others
Phase 1
171 of 1,928
61 open now
Registered
394th of 1,928
by date

Among the 1,928 studies in Breast Neoplasms with a site in China, this one is the 1,113th largest by enrollment of the 1,519 interventional ones that give a count, is one of 67 that started in 2017, is one of 171 in phase 1, and was the 394th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

866 of the 1,928 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

861 more — sign in →

All 866 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,928 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a Phase I, first-in-human, open-label, dose-escalation study of IMP4297 administered orally once every day to patients with advanced solid tumors for whom standard therapy either does not exist or has proven to be ineffective or intolerable. Patients with advanced breast cancer, ovarian cancer or prostate cancer are preferred. There are two stages to this study: a dose-escalation stage and a dose-expansion stage.

03

Conditions studied

  • Advanced Solid Tumours
  • Breast Cancer
  • Ovarian Cancer
  • Prostate Cancer

Keywords

  • Breast Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • Advanced solid tumours
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed Form
  2. 18 Years to 70 Years (including 18 and 75 years)
  3. or cytologically documented disease; incurable, advanced solid that has progressed on, or failed to respond to, at least one prior systemic therapy
  4. performance status of 0 or 1
  5. In the dose expansion stage, patients with BRCA (breast carcinoma) mutation will be enrolled. Patients with breast cancer, ovarian cancer and prostate cancer are preferred.
  6. In the dose escalation phase, at least one assessable lesion according to the 1.1 standard; In the dose expansion phase, at least one according to RECIST 1.1.

Exclusion criteria

Exclusion Criteria:

  1. Inadequate hematologic and organ function, defined by the following (hematologic parameters must be assessed ≥14 days after a prior treatment, if any):

    1. \<1500 cells/µL
    2. \< 9 g/dL
    3. Total > 1.5 × the (ULN), with documented liver total bilirubin > 3 × the ULN.
    4. (AST) and/or alanine transaminase (ALT) > 2.5 × the ULN, with documented liver metastases AST and/or ALT levels > 5 × the ULN.
    5. Serum creatinine > 1.5 × the ULN, or \< 45 mL/min based on a documented 24-hour urine collection or Cockcroft-Gault calculation of .
    6. (INR) > 1.5 × the ULN or activated partial thromboplastin time (aPTT) > 1.5 × the ULN.

    The INR applies only to patients who do not receive therapeutic anti-coagulation.

  2. Any anti-cancer therapy, including chemotherapy, hormonal therapy, biologic therapy, radiotherapy within 4 weeks prior to initiation of study treatment with the following exceptions:

    1. Hormonal therapy with gonadotropin-releasing hormone (GnRH) agonists for prostate cancer.
    2. Hormone-replacement therapy or oral .
    3. Palliative radiation to bone metastases > 2 weeks prior to Day 1.
  3. Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤ 1, except for alopecia.
  4. Prior therapies targeting PARP (poly-ADP ribose polymerase).
  5. Clinical significant active infection
  6. Known history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
  7. Known infection
  8. Class II or greater congestive heart failure; history of myocardial infarction or unstable angina within 6 months prior to Day 1; history of stroke or within 6 months prior to Day 1
  9. Active or untreated
  10. Pregnant (positive pregnancy test) or lactating women
  11. Male or female patients of child-producing potential unwilling to use double barrier contraception: condoms, sponge, foams, jellies, diaphragm or intrauterine device, contraceptives (oral, injectable or parenteral), implanon, or other avoidance of pregnancy measures during the study and for 90 days after the last day of treatment
  12. Inability to take oral medication, prior surgical procedures affecting absorption, or active peptic ulcer disease
  13. Inability to comply with study and follow-up procedures
  14. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an drug or that may affect the interpretation of the results or renders the patient at high risk from treatment complications.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    IMP4297

    Drug: IMP4297

Interventions

  • The dose levels will be escalated following a modified 3+3 dose escalation scheme.

06

What researchers measure

Primary outcomes

  1. The AEs (adverse event) of single and multiple doses of IMP4297 administered to participants with advanced solid tumors.

    Evaluate the TEAE (treatment-emergent adverse event) of IMP4297

    Time frame: Each visit after IMP4297 administrated (through study completion, an average of 10 months)

  2. The maximum tolerated dose (MTD) and evaluate the dose limiting toxicities (DLTs) of IMP4297

    Evaluate DLT and determine the MTD

    Time frame: Within 28 days after IMP4297 administrated

Secondary outcomes

  1. Area Under Curve [AUClast, AUCINF]

    Time frame: Within 7 days after firstly single dose administrated

  2. Area Under Curve [AUClast, AUCINF]

    Time frame: Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)

  3. Maximum plasma concentration (Cmax)

    Time frame: Within 7 days after firstly single dose administrated

  4. Maximum plasma concentration (Cmax)

    Time frame: Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)

  5. Time at which Cmax occurred (Tmax)

    Time frame: Within 7 days after firstly single dose administrated

  6. Time at which Cmax occurred (Tmax)

    Time frame: Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)

  7. Trough Concentrations (Ctrough)

    Time frame: Within 7 days after firstly single dose administrated

  8. Trough Concentrations (Ctrough)

    Time frame: Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)

  9. Clearance (CL/F)

    Time frame: Within 7 days after firstly single dose administrated

  10. Clearance (CL/F)

    Time frame: Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)

  11. Volume of distribution (Vd/F)

    Time frame: Within 7 days after firstly single dose administrated

  12. Volume of distribution (Vd/F)

    Time frame: Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)

07

Study locations

2 sites
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 200032, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Dec 2020, 39 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 39 months is close to that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2018
First posted
Apr 25, 2018
StartActual
Aug 23, 2017
Primary completionActual
Dec 16, 2020
CompletionActual
Dec 16, 2020
Last update
Mar 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03508011
Lead sponsor
Impact Therapeutics, Inc.
Responsible party
Sponsor
First posted
Apr 25, 2018
Start date
Aug 23, 2017
Primary completion
Dec 16, 2020
Completion
Dec 16, 2020
Last update
Mar 30, 2021

Study contacts

BingHe Xu, Doctor
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
JunNing Cao, Doctor
principal investigator · Fudan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Senaparib

Start the discussion